Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

First Posted Date
2018-06-27
Last Posted Date
2022-06-22
Lead Sponsor
Swedish Medical Center
Target Recruit Count
100
Registration Number
NCT03570983
Locations
🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

First Posted Date
2018-06-27
Last Posted Date
2024-12-20
Lead Sponsor
University of Chicago
Target Recruit Count
15
Registration Number
NCT03571321
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

Atovaquone (Mepron®) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML)

First Posted Date
2018-06-26
Last Posted Date
2024-11-21
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
26
Registration Number
NCT03568994
Locations
🇺🇸

Baylor College of Medicine - Texas Childrens Hospital, Houston, Texas, United States

🇺🇸

Johns Hopkins Medicine, Baltimore, Maryland, United States

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

First Posted Date
2018-06-21
Last Posted Date
2018-06-21
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
80
Registration Number
NCT03564704
Locations
🇨🇳

Department of Hematology, Nanfang Hospital, Guangzhou, Guangdong, China

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

First Posted Date
2018-06-20
Last Posted Date
2022-04-12
Lead Sponsor
Sumitomo Pharma Co., Ltd.
Target Recruit Count
10
Registration Number
NCT03563560
Locations
🇯🇵

Fukui University Hospital, Yoshida-gun, Fukui, Japan

🇯🇵

Chugoku Central Hospital, Fukuyama, Hiroshima, Japan

🇯🇵

Hokkaido University Hospital, Sapporo, Hokkaido, Japan

and more 8 locations

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

First Posted Date
2018-06-12
Last Posted Date
2018-06-12
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
70
Registration Number
NCT03553238
Locations
🇨🇳

Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm

First Posted Date
2018-05-22
Last Posted Date
2023-08-30
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
66
Registration Number
NCT03531918
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

First Posted Date
2018-05-09
Last Posted Date
2021-11-30
Lead Sponsor
University of Southern California
Target Recruit Count
3
Registration Number
NCT03519984
Locations
🇺🇸

USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

First Posted Date
2018-05-08
Last Posted Date
2022-11-04
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
6
Registration Number
NCT03518112
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Prospective Randomized Comparison of HDAC vs AD in the Induction Chemothrapy for AML.

First Posted Date
2018-04-25
Last Posted Date
2020-01-13
Lead Sponsor
Asan Medical Center
Target Recruit Count
380
Registration Number
NCT03507842
Locations
🇰🇷

Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy